We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In a new twist on the good news/bad news paradigm, the FDA has informed Perrigo to expect a complete response letter for its copy of Teva’s popular ProAir inhaler.